Gastroparesis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2034, as per DelveInsight

Gastroparesis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2034, as per DelveInsight

DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.


Key Takeaways from the Gastroparesis Market Report

  • The total Gastroparesis Market Size was found to be around USD 200 million in 2023 in the US, which is further expected to increase by 2034 with the approval of several new therapies in the market.
  • In 2023, the Gastroparesis market size of the United Kingdom accounted for approximately USD 10 million, which is expected to increase during the forecast period.
  • As per DelveInsight analysis, the Gastroparesis Market is anticipated to witness growth at a considerable CAGR.
  • The leading Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.
  • Promising Gastroparesis Therapies in the various stages of development include Velusetrag, tadalafil, PCS12852, Naronapride, and others.
  • April 2024:- CinDome Pharma Inc.- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis. The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.


Discover which therapies are expected to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook


Gastroparesis Overview

Gastroparesis is a condition that affects the stomach muscles, causing them to function improperly or not at all. This condition slows down or stops the movement of food from the stomach to the small intestine. Symptoms can include nausea, vomiting, abdominal pain, feeling full quickly when eating, and bloating. It’s often caused by damage to the vagus nerve, which controls the muscles of the stomach. Diabetes, certain medications, and surgery are common causes of gastroparesis. Treatment may include dietary changes, medications to stimulate stomach emptying, and in severe cases, surgery.


Gastroparesis Epidemiology Insights

The epidemiology section of Gastroparesis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.


Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiological Insights


Gastroparesis Marketed Therapies

  • GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma


Gastroparesis Emerging Therapies

  • VLY-686 (tradipitant): Vanda Pharmaceuticals
  • PCS12852: Processa Pharmaceuticals


Gastroparesis Drugs Market

The Gastroparesis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Gastroparesis signaling in Gastroparesis are likely to uncover new therapeutic targets and further expand treatment options for patients.


Gastroparesis Treatment Market Landscape

The Gastroparesis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Gastroparesis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.


To learn more about Gastroparesis treatment guidelines, visit @ Gastroparesis Treatment Market Landscape


Gastroparesis Market Outlook

The report’s outlook on the Gastroparesis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Gastroparesis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Gastroparesis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Gastroparesis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.


Gastroparesis Drugs Uptake

The drug chapter of the Gastroparesis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Gastroparesis.


Major Gastroparesis Companies

Several Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.


Learn more about the FDA-approved drugs for Gastroparesis @ Drugs for Gastroparesis Treatment


Scope of the Gastroparesis Market Report

  • Coverage- 7MM
  • Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.
  • Gastroparesis Therapies- Velusetrag, tadalafil, PCS12852, Naronapride, and others.
  • Gastroparesis Market Dynamics: Gastroparesis Market Drivers and Barriers
  • Gastroparesis Market Access and Reimbursement, Unmet Needs and Future Perspectives


Discover more about Gastroparesis Drugs in development @ Gastroparesis Clinical Trials Assessment


Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Gastroparesis

4. Gastroparesis Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Emerging Therapies

12. Gastroparesis: Six Major Market Analysis

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight


About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States